Table 3.

Time-to-onset analysis of SJS/TEN associated with anticancer therapies in the FAERS database.

Drugs	Cases*	TTO (days)		Webibull distribution				Failure type
				Scale parameter		Shape parameter
	n	Median	IQR	α	95%CI	β	95%CI
Anti-cancer drugs	1662	17	7-48	42.00	38.56-45.43	0.64	0.62-0.66	Early Failure
Pembrolizumab	135	32	13-82.5	65.29	50.28-80.30	0.79	0.69-0.89	Early Failure
Nivolumab	124	27	13-60.75	58.48	43.29-73.67	0.74	0.65-0.83	Early Failure
Carboplatin	97	31	10-64	49.73	37.43-62.02	0.86	0.73-0.98	Early Failure
Enfortumab Vedotin	77	14	10-21	24.97	18.35-31.59	0.91	0.77-1.05	Random Failure
Ipilimumab	41	19	9-41	35.94	19.30-52.57	0.70	0.55-0.85	Early Failure
Bendamustine	31	35	15-55	55.80	35.54-76.07	1.06	0.79-1.34	Random Failure
Atezolizumab	47	18	9.5-85	54.26	30.18-78.34	0.68	0.54-0.83	Early Failure
Vemurafenib	36	14	8.75-23.25	17.57	14.13-21.02	1.75	1.30-2.21	Wear-out Failure
Pemetrexed	50	25	6-92	54.91	34.27-75.56	0.83	0.65-1.02	Random Failure
Apalutamide	26	30	21-40.5	37.32	28.81-45.83	1.85	1.30-2.40	Wear-out Failure
Gemcitabine	32	12.5	3.75-36.25	34.92	16.82-53.01	0.73	0.54-0.93	Early Failure
Temozolomide	32	18.5	6.75-53.25	38.79	20.04-57.54	0.76	0.56-0.96	Early Failure
Sorafenib	46	9.5	6.25-12	17.51	10.07-24.96	0.73	0.60-0.87	Early Failure

* Only cases that reported a specific time of SJS/TEN onset and had a sample size greater than 20 were included in the time-to-onset analysis.α, scale parameter, represents the scale of the distribution function as the quantile in which 63.2% of AEs occur. β, shape parameter, could be used to confirm the distribution type: early failure type (β < 1), random failure type (95% CI of β include 1), and wear-out type (β > 1).